VivoSeq
Hematology

Primary Myelofibrosis

19

Pipeline Programs↗

2

Active Trials↗

11

Companies Involved↗

Primary Myelofibrosis is an emerging landscape with 19 programs across 11 companies. The most active players are AstraZeneca, Kura Oncology, Inc., Ipsen. 9 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

18/100

Completion Rate

63/100

Attrition Rate

30/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1K

Kura Oncology, Inc.

1 program

Phase 2Ipsen logo

Ipsen

1 program

Phase 2Roche logo

Roche

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 3Novartis logo

Novartis

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

18 of 19 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed5 · 50%
Terminated2 · 20%
Withdrawn1 · 10%
Recruiting1 · 10%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06327100·33 enrolled
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies
Active, not recruiting·Novartis logoNovartis·Approved·NCT02386800·279 enrolled
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02098161·50 enrolled
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Completed·Novartis logoNovartis·Phase 4·NCT01558739·48 enrolled
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
Completed·Novartis logoNovartis·Phase 2·NCT01392443·120 enrolled
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Completed·PPharmaMar·Phase 2·NCT01149681·12 enrolled
Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg
Completed·FFrench Innovative Leukemia Organisation·Phase 1/2·NCT02742324·37 enrolled
Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Terminated·WWeill Medical College of Cornell University·Phase 2·NCT01758588·8 enrolled
A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis
Terminated·Novartis logoNovartis·Phase 2·NCT00931762·35 enrolled
PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04054245

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)